Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Chronic Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 10, 2009, Pages 1331-1336

  Villanueva, Fernanda N ^a   Pérez Simón, Jose Antonio ^a   Silva, Fernando F ^a   Caballero Velázquez, Teresa T ^a   Sánchez Guijo, Fermin F ^a   Cañizo, Conzuelo C ^a   Vázquez, Lourdes L ^a   Caballero, Dolores D ^a   San Miguel, Jesús F ^a  

^a Centro de Investigacion del Cancer   (Spain)

Author keywords

Allogeneic stem cell transplantation; BDP; Beclomethasone dipropionate; cGVHD; Gastrointestinal chronic graft versus hot disease

Indexed keywords

ALEMTUZUMAB; BECLOMETASONE DIPROPIONATE; CYCLOSPORIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CUSHING SYNDROME; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; MALE; MUSCULOSKELETAL PAIN; MYCOSIS; OVERALL SURVIVAL; RELAPSE; REMISSION; VIRUS REACTIVATION;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; BECLOMETHASONE; BIOPSY; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 69749093177     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.05.018     Document Type: Article

References (29)

1. Martin P.J., Weisdorf D., Przepiorka D., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant 12 (2006) 491-505
2. Perez-Simon J.A., Sanchez-Abarca I., Diez-Campelo M., Caballero D., and San M.J. Chronic graft-versus-host disease: pathogenesis and clinical management. Drugs 66 (2006) 1041-1057
3. Martin P.J., McDonald G.B., Sanders J.E., et al. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 10 (2004) 320-327
4. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 11 (2005) 945-956
5. Ferrara J.L., and Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 43 (2006) 3-10
6. Lee S.J., Klein J.P., Barrett A.J., et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 100 (2002) 406-414
7. Sullivan K.M., Witherspoon R.P., Storb R., et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 72 (1988) 546-554
8. Sullivan K.M., Shulman H.M., Storb R., et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 57 (1981) 267-276
9. Koc S., Leisenring W., Flowers M.E., et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 100 (2002) 48-51
10. Horwitz M.E., and Sullivan K.M. Chronic graft-versus-host disease. Blood Rev 20 (2006) 15-27
11. Rohdewald P., Mollman H.W., and Hochhaus G. Affinities of glucocorticoids for glucocorticoid receptors in the human lung. Agents Actions 17 (1986) 290-291
12. Wurthwein G., and Rohdewald P. Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monopropionate. Biopharm Drug Dispos 11 (1990) 381-394
13. Daley-Yates P.T., Price A.C., Sisson J.R., Pereira A., and Dallow N. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 51 (2001) 400-409
14. Hockenbery D.M., Cruickshank S., Rodell T.C., et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 109 (2007) 4557-4563
15. Brogden R.N., Pinder R.M., Sawyer P.R., Speight T.M., and Avery G.S. Beclomethasone dipropionate inhaler: a review of its pharmacology, therapeutic value and adverse effects. I: Asthma. Drugs 10 (1975) 166-210
16. Diez-Campelo M., Sanchez-Guijo F.M., and Perez-Simon J.A. Beclomethasone dipropionate: a topically active corticosteroid for the treatment of gastrointestinal graft-versus-host disease. Expert Opin Invest Drugs 17 (2008) 1389-1401
17. McDonald G.B. Oral beclomethasone dipropionate: a topically active corticosteroid for the treatment of gastrointestinal graft-versus-host disease following allogeneic hematopoietic cell transplantation. Expert Opin Invest Drugs 16 (2007) 1709-1724
18. Castilla C., Perez-Simon J.A., Sanchez-Guijo F.M., et al. Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus-host disease (GVHD). Biol Blood Marrow Transplant 12 (2006) 936-941
19. McDonald G.B., Bouvier M., Hockenbery D.M., et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology 115 (1998) 28-35
20. Iyer R.V., Hahn T., Roy H.N., et al. Long-term use of oral beclomethasone dipropionate for the treatment of gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant 11 (2005) 587-592
21. Pavletic S.Z., Martin P., Lee S.J., et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 12 (2006) 252-266
22. Perez-Simon J.A., Encinas C., Silva F., et al. Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the National Institutes Health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy. Biol Blood Marrow Transplant 14 (2008) 1163-1171
23. Martino R., Caballero M.D., Perez-Simon J.A., et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 100 (2002) 2243-2245
24. Ringden O., Hermans J., Labopin M., et al. The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). Leuk Lymphoma 24 (1996) 71-79
25. Valcarcel D., Martino R., Caballero D., et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 26 (2008) 577-584
26. Perez-Simon J.A., Caballero D., Diez-Campelo M., et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 16 (2002) 1423-1431
27. Lee S.J., Vogelsang G., Gilman A., et al. A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant 8 (2002) 32-39
28. Baehr P.H., Levine D.S., Bouvier M.E., et al. Oral beclomethasone dipropionate for treatment of human intestinal graft-versus-host disease. Transplantation 60 (1995) 1231-1238
29. Rautiainen H., Karkkainen P., Karvonen A.L., et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 41 (2005) 747-752